GOING CONCERN	12 Months Ended
Mar. 31, 2022
GOING CONCERN
GOING CONCERN	NOTE 2 - GOING CONCERN As indicated in the accompanying consolidated financial statements, the Company had a net loss of approximately $16.8 million for the year ended March 31, 2022 and approximately $34.8 million for the year ended March 31, 2021. The net cash used in operating activities was US$6.8 million for the year ended March 31, 2022 and the net cash provided by operating activities was US$10.2 million for the year ended March 31, 2021. Management of the Company has considered whether there is substantial doubt about its ability to continue as a going concern due to the Company’s planned new business as a cancer therapy and radiotherapy oncology service provider and volatile market conditions arising from the COVID-19 pandemic, and evaluated its available cash balance against its working capital requirements and investment to the cancer centers over the next twelve months. While management cannot accurately predict the prospects and regulatory environment of the social E-commerce industry and healthcare service industry and the full impact of COVID-19 on the Company’s business in fiscal year 2023, the management believes that the Company would have sufficient funds to meet its working capital requirements for fiscal year 2023, and that its capital resources are currently sufficient to maintain its business operations for the next twelve months. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

GOING CONCERN

12 Months Ended

Mar. 31, 2022

NOTE 2 - GOING CONCERN

As indicated in the accompanying consolidated financial statements, the Company had a net loss of approximately $16.8 million for the year ended March 31, 2022 and approximately $34.8 million for the year ended March 31, 2021. The net cash used in operating activities was US$6.8 million for the year ended March 31, 2022 and the net cash provided by operating activities was US$10.2 million for the year ended March 31, 2021. Management of the Company has considered whether there is substantial doubt about its ability to continue as a going concern due to the Company’s planned new business as a cancer therapy and radiotherapy oncology service provider and volatile market conditions arising from the COVID-19 pandemic, and evaluated its available cash balance against its working capital requirements and investment to the cancer centers over the next twelve months.

While management cannot accurately predict the prospects and regulatory environment of the social E-commerce industry and healthcare service industry and the full impact of COVID-19 on the Company’s business in fiscal year 2023, the management believes that the Company would have sufficient funds to meet its working capital requirements for fiscal year 2023, and that its capital resources are currently sufficient to maintain its business operations for the next twelve months.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and/or classification of the recorded asset amounts and/or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.